Breaking — April 22, 2026. The Acting Attorney General signed a DEA Final Order that does two things that have never been done in the 55 years of the Controlled Substances Act. First, it moves FDA-approved cannabis drug products and any marijuana subject to a state medical marijuana license from Schedule I to Schedule III. Second, it opens a brand-new federal cannabis license — an expedited DEA registration pathway at 21 CFR § 1301.13(k) — that uses your state medical license as conclusive evidence of state-law authorization.
Translation for the people who actually have to run a business: the feds just built you an on-ramp. The first 60 days of that on-ramp come with a superpower. Miss it, and you’re playing regular season rules with no possession advantage.
Here’s the practitioner’s walkthrough — what changed, what didn’t, and the 10 critical steps you should be executing this week if you hold (or will hold) a state medical marijuana license.
What the DEA actually did on April 22, 2026
The Acting Attorney General used the treaty pathway at 21 U.S.C. § 811(d)(1), which lets the agency reschedule without the usual 21 U.S.C. § 812(b) findings or APA notice-and-comment rulemaking when control is required to comply with the Single Convention on Narcotic Drugs. Relying on an April 2024 OLC opinion and the August 2023 HHS Basis for Recommendation, the Order:
- Adds three new entries to Schedule III at 21 CFR § 1308.13(g)(2)–(4): (i) marijuana in an FDA-approved product or subject to a state medical marijuana license; (ii) marijuana extract in the same; and (iii) naturally-derived Δ9-THC in the same.
- Creates a new federal cannabis license — an expedited DEA registration pathway at 21 CFR § 1301.13(k) — specifically for state medical marijuana licensees.
- Amends 21 CFR § 1312.30 to keep the import/export permit requirement attached (Single Convention Article 31 still requires a permit).
- Leaves unlicensed bulk marijuana, adult-use marijuana, synthetic THC, and previously-scheduled products (Marinol, Syndros) untouched.
Effective date: April 22, 2026. No phase-in, no comment window on the scheduling action itself. It’s live.
The new federal cannabis license, decoded
This is the part that matters. The DEA has never — never — granted a state-licensed medical marijuana operator federal authority to manufacture, distribute, or dispense marijuana for medical purposes. As of this week, they have a framework to do exactly that, and they have to grant the registration unless it’s inconsistent with the public-interest factors at 21 U.S.C. § 823(e)–(g) or the Single Convention.
The nuts and bolts of 21 CFR § 1301.13(k):
- Four registration types — marijuana manufacturer, distributor, dispenser, or (with a separate § 1301.13 researcher registration) researcher. A single entity can hold multiple types.
- State license = conclusive evidence. For purposes of § 823(e)–(g), your state medical marijuana license is conclusive evidence that you’re authorized under state law. No DEA re-litigation of your state application.
- Shall-grant posture. The Administrator shall register the applicant unless registration is inconsistent with the public interest or the Single Convention. That’s different from ordinary DEA discretion — it’s a thumb on the scale for applicants.
- Scope tethered to state. Your DEA registration cannot exceed the scope of your state license, and it automatically suspends if your state license is suspended, revoked, or expires.
- State records accepted. The Administrator “shall accept state-required reports, records, and forms to the maximum extent permissible.”
- State certifications work as prescriptions. A medical marijuana certification that’s sufficient under state law — dated, signed, with the patient’s name and address and the certifying practitioner’s state license — satisfies federal dispensing requirements. No separate DEA prescription form.
- State labeling, packaging, disposal, and security OK. Part 1302, Part 1317, and the federal physical-security rules step aside if you’re complying with state law — subject to the 21 U.S.C. § 825(c) warning label.
If that sounds like cooperative federalism written into the CFR, it is. The Order explicitly says so. Operators should be reading their existing state compliance SOPs through this lens — most of what you already do will satisfy federal requirements on day one, and your consulting team can tell you what gaps to close. Inside your individual state’s licensing framework, the overlay looks different depending on your market — our state-by-state cannabis licensing hub is the starting point if you need a refresher.
The 60-day window nobody should miss
Here’s the provision I want tattooed on every operator’s forearm:
“Notwithstanding subsection (a), any applicant that submits an application within 60 days of the publication of this rule in the Federal Register may engage in the manufacture, distribution, and/or dispensing of marijuana or products containing marijuana for medical purposes in conformity with a state-issued license during the pendency of the application.” — 21 CFR § 1301.13(k)(7)
Read that again. Applicants who file within 60 days of Federal Register publication can continue operating under their state license while DEA reviews their federal application, and the Administrator “shall make every effort” to decide those applications within six months.
Applicants who file on day 61 or later? No early-operating right. You’re in the regular queue, and you’re not federally authorized until DEA signs off.
Translation: every operator with a state medical license has two jobs for the next eight weeks — gather the paperwork and file. The people who move first keep their doors open and add federal legitimacy on top of their state license. The people who wait “to see what happens” hand that advantage to their competitors.
10 critical steps for your federal cannabis license application
1. Pull your state license file for the federal cannabis license application
DEA’s new pathway requires “proof of a state medical marijuana license in the form specified by the Administrator.” Until the Administrator publishes that form, pull your state-issued license certificate, your approval letter, your most recent state renewal, and any state compliance audit reports. You’ll need them in a federally-organized file folder anyway.
2. Map every activity on your state license to a federal cannabis license registration type
§ 1301.13(k)(1) creates four discrete types: manufacturer (cultivate, produce, process, package, label, transfer), distributor (receive and transfer between registered manufacturers, distributors, and dispensers), dispenser (transfer to state-authorized medical users), and researcher (§ 1301.13 registration with state-licensed product allowed). Vertically-integrated operators need multiple registrations. Map which activities you conduct under state law to which federal types you’ll need.
3. Designate your cultivation areas with precision
For manufacturer registrants, § 1301.13(k)(6)(C) requires your registration to “specify the areas in which marijuana cultivation is permitted.” DEA inspectors will hold you to those parcels. Before you apply, nail down your cultivation footprint — grow rooms, greenhouse zones, outdoor parcels, tissue-culture labs — with legal descriptions or parcel numbers.
4. Prepare for the nominal-price purchase-and-resale mechanism
This is weird, but it’s how the DEA satisfies Single Convention Articles 23 and 28 without actually monopolizing your wholesale trade. Under § 1301.13(k)(6)(A)–(B), the DEA buys your harvested crops at a nominal price you set, then immediately sells them back at the same price plus a Part 1318.06(a) administrative fee. You have to store the crops in a facility where DEA has access until the transaction closes. Budget for the administrative fee and build the storage access protocol into your SOPs.
5. Budget the federal cannabis license registration fees
Under 21 CFR Part 1301, current DEA registration fees are $3,699 annually for manufacturers, $1,850 annually for distributors, and $888 for dispensers (3-year term). A vertically-integrated MSO with cultivation, processing, distribution, and multiple dispensaries is looking at five figures a year in federal fees before the state line items. Plan for it.
6. Audit your recordkeeping against federal minimums
§ 1301.13(k)(4) limits federal reporting and recordkeeping to “what the Administrator concludes are necessary to comply with federal statutory and treaty obligations” — and the Administrator shall accept your state reports to the maximum extent permissible. But you still have to produce records on request, and a federal registrant with sloppy state records loses the benefit of this provision fast. Use the 60-day window to clean up your seed-to-sale data, inventory reconciliations, and disposal logs. Run an operational compliance audit — this is exactly where a consulting team earns its fee.
7. Align your federal cannabis license dispensing paperwork with § 1301.13(k)(5)
The Order accepts a state medical marijuana certification as sufficient for federal dispensing, but only if it includes the patient’s full name and address, is dated as of and signed on the day of issuance, and lists the certifying practitioner’s name, address, and state license number. Walk through a random week of certifications you’ve accepted. If any are missing those fields, fix the intake process now. Post-registration, that single missing field becomes a federal recordkeeping problem.
8. Plan for the import/export permit if you move product across borders
Even though marijuana is now in Schedule III for registered state licensees, the Order amends 21 CFR § 1312.30 to keep the import/export permit requirement attached. If you import terpenes, flavorings, or any finished product containing marijuana — or if your multi-state operation contemplates interstate movement once that’s legal — you’ll need an import/export permit on top of the § 1301.13(k) registration.
9. Get your federal cannabis license Section 280E tax strategy refreshed
This is the sleeper value of the entire Order. Section 280E disallows ordinary business deductions for any trade or business “trafficking in controlled substances… in a schedule I or II.” State-licensed medical marijuana is now in Schedule III. The Order explicitly says state licensees “will no longer be subject to the deduction disallowance imposed by Section 280E” and encourages the Treasury Secretary “to consider providing retrospective relief” for past taxable years.
The Order also explicitly says it is not itself a tax determination — talk to tax counsel before you file anything. But plan on a materially different effective tax rate going forward, and plan on a good-faith retrospective 280E refund argument for open years. This is the biggest balance-sheet event in the history of state-licensed cannabis.
10. Decide who in your org owns the federal cannabis license file
DEA registrants answer to the Administrator. Someone in your company — compliance officer, general counsel, or an outside federal regulatory counsel — needs to own the federal file the way your director of compliance owns your state file. They’ll manage the registration, annual renewals, the biennial inventory, import/export permits, and any DEA correspondence. If that role doesn’t exist today, create it before the federal paperwork starts arriving. A cannabis compliance consulting team can stand that function up inside your existing org before the federal paperwork starts arriving.
What did NOT change on April 22
Read the exclusions closely, because this is where operators misread breaking news and get themselves in trouble.
- Adult-use / recreational marijuana remains Schedule I. The Order applies only to FDA-approved products and marijuana subject to a state medical marijuana license. If your state license is adult-use only, you’re still trafficking a Schedule I substance under federal law.
- Unlicensed bulk marijuana stays in Schedule I. Grey-market operators, unlicensed collectives, and anyone operating outside a state licensing regime get nothing from this Order.
- Synthetic THC stays in Schedule I. Delta-10, synthetic delta-9, and any tetrahydrocannabinols derived through artificial synthesis are explicitly excluded. HHS’s scientific evaluation only covered plant-derived marijuana.
- Hemp is unaffected — for now. The Order notes that the definition of hemp at 7 U.S.C. § 16390 is being amended effective November 12, 2026 to reference “total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid)” rather than just Δ9-THC. That’s a separate earthquake for the hemp industry, and I’ll cover it in a separate post.
- Previously-scheduled products (Marinol, Syndros) are unaffected. They stay where they are.
- Criminal liability still attaches to any activity outside the federal registration.
The 280E bombshell deserves its own bullet
For two decades, the single largest drag on state-licensed cannabis margins has been Section 280E — the provision that turned otherwise-profitable dispensaries into companies paying federal income tax on gross profit because they couldn’t deduct rent, payroll, marketing, or professional fees. (We’ve written about the 280E tax problem more times than any of us can count.) As of April 22, 2026, state-licensed medical marijuana is no longer in Schedule I or II. The statutory trigger for 280E disallowance goes away.
The Order makes two moves worth noting. First, it directly tells state licensees they “will no longer be subject to the deduction disallowance.” Second, it “encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.” The second point is the one nobody’s talking about yet — retrospective relief on open tax years could mean seven-figure refund claims for mature operators.
This is not tax advice. Get with your CPA and your tax counsel this quarter. The Order itself says so.
Research, liability, and the “federalism” safety valve
A small provision in the Order solves a problem researchers have been screaming about for a decade. Under 21 CFR § 1301.13 as amended, a DEA-registered researcher who obtains marijuana or marijuana products from a state licensee “shall incur no civil or criminal liability under the Controlled Substances Act solely by reason of having obtained such products from a state-licensed source” — provided the researcher holds a § 1301.13 registration and the state licensee held a valid federal registration at the time of transfer. Translation: university labs and clinical researchers can finally study the products their patients actually consume.
Liability otherwise still attaches. Any activity outside the scope of your § 1301.13(k) registration is unlawful and can subject you to administrative, civil, and criminal sanctions. The federal umbrella doesn’t cover anything your state license doesn’t cover first.
Frequently asked questions about the federal cannabis license
Is Schedule III the same as federal legalization?
No. Schedule III is a rescheduling, not a descheduling. Marijuana remains a controlled substance under federal law. What changed is that state-licensed medical operators and FDA-approved drug products now sit in a schedule with ketamine and certain steroids rather than heroin and LSD, and the DEA now has a registration framework built specifically for state medical licensees. Adult-use remains Schedule I under federal law.
Do I need a DEA registration if I only hold a state adult-use license?
The § 1301.13(k) pathway is only open to holders of a state medical marijuana license. If you’re adult-use only, this Order does not apply to your operation. Your state-licensed adult-use activity remains federally illegal under Schedule I.
What happens to my federal registration if my state license lapses?
It automatically suspends. Under § 1301.13(k)(3), “if the state medical marijuana license is suspended, revoked, or expires, the federal cannabis license is automatically suspended.” Keep your state renewals in front of your federal renewals on your compliance calendar.
Does this mean I can move product across state lines?
No. Your § 1301.13(k) registration cannot exceed the scope of your state license. State licenses don’t authorize interstate commerce. Until Congress or the states open interstate cannabis commerce, your federal registration stays inside your state’s regulatory box.
How long does the expedited review take?
For applications submitted within 60 days of Federal Register publication, the Administrator “shall make every effort” to process within six months, and the applicant may operate under the state license during pendency. For applications submitted after the 60-day window, there’s no statutory timeline and no early-operating right.
Does the Final Order apply to CBD products?
Not directly. CBD products derived from hemp remain unaffected. CBD products that are FDA-approved drug products containing CBD with ≤0.1% THC were already placed in Schedule V in 2018. The new Order covers FDA-approved marijuana drug products and state-licensed medical marijuana — which includes the full-spectrum THC-containing products that were previously Schedule I.
Will the Final Order be challenged in court?
Probably. The Order’s use of the § 811(d)(1) treaty pathway is aggressive, and courts have previously suggested HHS input is required in some contexts. DEA addresses this by pointing to the August 2023 HHS Letter and Basis for Recommendation. Expect challenges from abstinence-focused advocacy organizations and from states that oppose medical marijuana. Plan as if the federal cannabis license Order survives, and build your compliance anyway — the downside of a filed, pending federal application is essentially zero.
Our federal cannabis compliance team is taking calls this week
If you hold a state medical marijuana license and you want to be inside that 60-day window, the runway is short. We’re helping operators this week with:
- Federal cannabis license application drafting and filing under 21 CFR § 1301.13(k)
- SOP and recordkeeping alignment to federal minimums
- Corporate restructuring where the federal registrant needs to be a different entity than the state licensee
- Section 280E forward-planning and retrospective refund strategy
- Import/export permit applications for finished-product and ingredient movement
Book a confidential federal cannabis license consultation, or watch the latest Cannabis Legalization News episode where we’re breaking this down all week. The applicants who file in the first 60 days are the ones who walk into 2027 with a federal cannabis license, a better effective tax rate, and a balance sheet that doesn’t apologize for itself.
{
“@context”: “https://schema.org”,
“@type”: “Article”,
“headline”: “Federal Cannabis License: 10 Critical DEA Steps After Schedule III”,
“description”: “The DEA’s April 22, 2026 Final Order moves state-licensed medical marijuana to Schedule III and opens an expedited federal cannabis license. Your 60-day play.”,
“author”: {
“@type”: “Person”,
“name”: “Thomas Howard”,
“url”: “https://cannabisindustrylawyer.com/about/”
},
“publisher”: {
“@type”: “Organization”,
“name”: “Cannabis Industry Lawyer”,
“url”: “https://cannabisindustrylawyer.com/”
},
“datePublished”: “2026-04-23”,
“dateModified”: “2026-04-23”,
“image”: “https://cannabisindustrylawyer.com/wp-content/uploads/2026/04/federal-cannabis-license.webp”,
“mainEntityOfPage”: “https://cannabisindustrylawyer.com/federal-cannabis-license-dea-schedule-iii/”
}
{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{“@type”:”Question”,”name”:”Is Schedule III the same as federal legalization?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. Schedule III is a rescheduling, not a descheduling. Marijuana remains a controlled substance under federal law. State-licensed medical operators and FDA-approved drug products now sit in Schedule III, while adult-use marijuana remains Schedule I.”}},
{“@type”:”Question”,”name”:”Do I need a DEA registration if I only hold a state adult-use license?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The 21 CFR 1301.13(k) pathway is only open to holders of a state medical marijuana license. State-licensed adult-use operations remain federally illegal under Schedule I.”}},
{“@type”:”Question”,”name”:”What happens to my federal cannabis license if my state license lapses?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”It automatically suspends. If the state medical marijuana license is suspended, revoked, or expires, the DEA registration is automatically suspended.”}},
{“@type”:”Question”,”name”:”Does this mean I can move product across state lines?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. Your federal registration cannot exceed the scope of your state license, and state licenses do not authorize interstate commerce.”}},
{“@type”:”Question”,”name”:”How long does the expedited DEA review take?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”For applications filed within 60 days of Federal Register publication, the Administrator shall make every effort to process within six months, and the applicant may operate under the state license during pendency.”}}
]
}